Dean Tuck – Managing Director – Dreadnought Resources (ASX:DRE) is a highly active West Australian mineral explorer focused on finding the metals needed now and in the future.
Copyright 2024 – Finance News Network
27 May 2022 - TerraCom Limited (ASX:TER) Executive Chairman Craig Ransley discusses drivers behind the company's performance and share price over the previous year.
16 Aug 2023 - Mark Leong - Executive Chairman - Osteopore (ASX:OSX) is a Singapore-headquartered corporation poised to be a leading medical device company in the region. It is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery use.
20 Nov 2019 - Ausbil Investment Management Chief Investment Officer, Paul Xiradis and Ausbil Head of ESG Research, Måns Carlsson-Sweeny, provide an update on the Ausbil Active Sustainable Equity fund’s performance, talk about what the fund looks for in businesses that fit the description of "sustainable", and discuss how these characteristics provide long-term above-market returns.
27 Jun 2022 - North Stawell Minerals Limited (ASX:NSM) CEO Russell Krause discusses recent drilling results, plans through the winter months, and outlook.
20 Jan 2021 - National Retail Association CEO Dominique Lamb discusses retail performance over the Christmas period, trends in retail, and strategies for encouraging consumer spending.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
16 Dec 2019 - Openpay Group (ASX:OPY) CEO & MD, Michael Eidel talks about its business model, size of the opportunity and how it differentiates itself from other buy now pay later (BNPL) providers.
18 Dec 2019 - Prospect Resources Limited (ASX:PSC) Managing Director, Sam Hosack, provides an update on the company's Arcadia lithium project in Zimbabwe, including advanced negotiations with a number of African and international banks on funding.
06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.
25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.